Compare Danaher Corporation (DHR) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Goldman Sachs Group Inc — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Goldman Sachs Group Inc trades at $1,139 (market cap $336.31B). The key difference: Goldman Sachs Group Inc is far larger — about 2.4× Danaher Corporation's market cap, and Goldman Sachs Group Inc pays the higher dividend (1.58%). Which is the better fit depends on your goals.
| DHR | GS | |
|---|---|---|
Market Cap | $140.88B | $336.31B |
Sector | Health | Financials |
52-Week High | $242.05 | $1.14K |
52-Week Low | $161.91 | $700.41 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 1.58% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Goldman Sachs (GS) trades at $1,140, up 8.04% in the past 24 hours, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.89% net income margin and 15.69% ROE, supported by positive analyst sentiment and involvement in high-profile IPOs like Anthropic. Revenue growth accelerated to $58.28 billion in 2025, though cash flow trends remain volatile.
The outlook for GS is positive, driven by investment banking strength and AI-driven IPO opportunities, but risks include negative operating cash flows and elevated debt levels. Analysts maintain a consensus price target of $1,080, with 40% recommending Buy. Investors should weigh the company's profit growth against liquidity concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
